Ä¢¹½ÊÓƵAPP

Brenda Eustace joined Ä¢¹½ÊÓƵAPP in 2021 as Vice President, Head of Biology for Pioneering Medicines. She leads a team of scientists who collaborate with Pioneering Medicines project teams, Flagship platform companies, and external strategic partners to advance a portfolio of therapeutic programs towards clinical development.

Brenda brings more than 15 years of pharmaceutical research and development experience from Vertex Pharmaceuticals, where she led teams from pre-clinical research to clinical proof-of-concept. Prior to joining Flagship, she led projects across multiple therapeutic areas and modalities, including, notably, the research and early development collaboration with CRISPR Therapeutics for the CTX001â„¢ program. This program, the first ex vivo CRISPR/Cas9 gene-editing therapy to be brought to the clinic from the private sector, demonstrated proof-of-concept in both beta-thalassemia and sickle cell disease, and is currently in Phase 3 clinical studies. Additionally, Brenda and her team enabled multiple regulatory submissions in other therapeutic areas, including oncology and infectious disease and spearheaded numerous academic and CRO collaborations. Most recently at Vertex, Brenda worked on the Investor Relations team where she was responsible for externally communicating corporate strategy, the science of pipeline programs, and financials to investors and analysts.

Brenda earned her Ph.D. from Tufts Graduate School of Biomedical Sciences where she invented new technologies to study the role of extracellular factors involved in cancer metastasis.